A case of hoarseness of voice following COVID-19 infection

Submitted: November 3, 2022
Accepted: December 27, 2022
Published: January 27, 2023
Abstract Views: 754
PDF: 204
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Mucormycosis is a fatal angio-invasive fungal infection associated with a high mortality. Apart from the traditional risk factors, COVID-19 infection and steroid therapy for the same have been recently identified to predispose to this life-threatening infection. Usual presentations of mucormycosis include rhino-orbito-cerebral, pulmonary, gastrointestinal, renal and cutaneous involvement. We report an unusual case of mediastinal involvement by mucormycosis in a patient recovering from moderate COVID-19 pneumonia. Early diagnosis, prompt initiation of antifungal therapy accompanied by timely surgical debridement were pivotal in averting morbidity and mortality in this patient.



PlumX Metrics


Download data is not yet available.


Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol 2019;57:395-402. DOI: https://doi.org/10.1093/mmy/myy060
Landstra CP, de Koning EJP. COVID-19 and diabetes: Understanding the interrelationship and risks for a severe course. Front Endocrinol 2021;12:649525. DOI: https://doi.org/10.3389/fendo.2021.649525
Muthu V, Rudramurthy SM, Chakrabarti A, et al. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia 2021;186:739–54. DOI: https://doi.org/10.1007/s11046-021-00584-8
Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 2022;3:e543–52. DOI: https://doi.org/10.1016/S2666-5247(21)00237-8
Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐ and middle‐income countries. Mycoses 2021;64:1028–37. DOI: https://doi.org/10.1111/myc.13335
Dhooria S, Agarwal R, Chakrabarti A. Mediastinitis and bronchial perforations due to mucormycosis. J Bronchol Interv Pulmonol 2015;22:338–42. DOI: https://doi.org/10.1097/LBR.0000000000000170
Connor BA, Anderson RJ, Smith JW. Mucor mediastinitis. Chest 1979;75:524–6. DOI: https://doi.org/10.1378/chest.75.4.524
Liu HC, Jan MS, Lin YC, et al. A rare pulmonary zygomycosis manifested as chronic mediastinitis and bronchial perforation. Eur Respir J 2011;38:734–5. DOI: https://doi.org/10.1183/09031936.00155110
Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis 2022;22:e240-53. DOI: https://doi.org/10.1016/S1473-3099(22)00124-4
Cooper JD, Gotoff RA, Foltzer MA, et al. Mediastinal mucormycosis: Case report, review of literature and treatment with continuous liposomal amphotericin B irrigation. Mycoses 2019;62:739-45. DOI: https://doi.org/10.1111/myc.12922

How to Cite

Joseph, Ruby, Kavitha Venkatnarayan, Ashitha Nanaiah, and Priya Ramachandran. 2023. “A Case of Hoarseness of Voice Following COVID-19 Infection”. Monaldi Archives for Chest Disease 93 (4). https://doi.org/10.4081/monaldi.2023.2472.